|
|
|
|
| LEADER |
00000cam a2200000Ia 4500 |
| 001 |
SCIDIR_on1334332815 |
| 003 |
OCoLC |
| 005 |
20231120010652.0 |
| 006 |
m o d |
| 007 |
cr un|---aucuu |
| 008 |
220704s2022 mau o 000 0 eng d |
| 040 |
|
|
|a YDX
|b eng
|c YDX
|d OPELS
|d SFB
|d OCLCF
|d OCLCQ
|d OCLCO
|
| 020 |
|
|
|a 9780323900881
|q (electronic bk.)
|
| 020 |
|
|
|a 0323900887
|q (electronic bk.)
|
| 020 |
|
|
|z 9780323900874
|
| 020 |
|
|
|z 0323900879
|
| 035 |
|
|
|a (OCoLC)1334332815
|
| 050 |
|
4 |
|a RC270.8
|
| 082 |
0 |
4 |
|a 616.99406
|2 23
|
| 245 |
0 |
0 |
|a Strategies to mitigate the toxicity of cancer therapeutics /
|c edited by David A. Gewirtz, Paul B. Fisher.
|
| 260 |
|
|
|a Cambridge, MA :
|b Academic Press,
|c 2022.
|
| 300 |
|
|
|a 1 online resource.
|
| 490 |
1 |
|
|a Advances in cancer research ;
|v v. 155
|
| 505 |
0 |
|
|a Intro -- Strategies to Mitigate the Toxicity of Cancer Therapeutics -- Copyright -- Contents -- Contributors -- Preface -- Chapter One: An overview of chemotoxicity and radiation toxicity in cancer therapy -- 1. Introduction -- 2. Cardiotoxicity -- 3. Pulmonary toxicity -- 4. Renal toxicity -- 5. Gastrointestinal toxicity -- 5.1. Chemotherapy-induced nausea and vomiting (CINV) -- 5.2. Severe delayed onset diarrhea -- 5.3. Mucositis -- 6. Neuromuscular toxicity -- 6.1. Chemotherapy-induced peripheral neuropathy (CIPN) -- 7. Cognitive dysfunction associated with chemotherapy: ``Chemobrain or chemo fog�� -- 8. Myalgias and arthralgias -- 9. Cutaneous toxicity -- 10. Secondary malignancies -- 11. Side effects of immune checkpoint inhibitors -- 12. Radiation therapy -- 12.1. CNS -- 12.2. Head and neck -- 12.3. Breast -- 12.4. Lung -- 12.5. Upper abdomen -- 12.6. Lower abdomen and pelvis -- 13. Mitigating/circumventing chemotoxicity -- 14. Conclusion -- References -- Chapter Two: Chemobrain: A review on mechanistic insight, targets and treatments -- 1. Introduction -- 2. Impact of chemobrain in patients -- 3. Symptoms and epidemiology -- 4. Mechanisms contributing to chemobrain -- 4.1. Oxidative stress -- 4.1.1. Occurrence of ROS and its activity -- 4.1.2. Antioxidants and their protective role -- 4.2. Absence of spinal and dendritic arborization -- 4.3. Inflammatory cytokines -- 4.4. Neurotransmitters -- 4.5. Apoptosis and autophagy -- 4.6. MAPK signalling pathway -- 4.7. Genetic factors and epigenetic modulations -- 5. Targets and treatment options -- 5.1. Targeting oxidative stress -- 5.2. Targeting neurogenesis -- 5.3. Targeting neuroinflammation -- 5.4. Targeting arborization -- 5.5. Targeting genetic factors -- 6. Current status and personalized therapy -- 7. Future perspectives -- 8. Conclusion -- Reference -- Further reading.
|
| 505 |
8 |
|
|a Chapter Three: Nephrotoxicity in cancer treatment: An update -- 1. Introduction -- 2. Risk factors for renal toxicities in cancer therapy -- 2.1. General risk factors for nephrotoxicity of anticancer drugs and treatment -- 2.2. Patient-specific factors -- 2.3. Kidney-specific factors -- 2.3.1. Genetic polymorphisms, sex and other kidney-related factors in renal enzymes -- 2.4. Drug-specific factors -- 3. Nephrotoxicity of chemotherapeutic agents and management -- 3.1. Platinum agents -- 3.1.1. Prospective use of diabetes drugs -- 3.1.2. Prospective use of antihypertensive agents -- 3.1.3. Prospective use of other clinically available drugs -- 3.1.4. Prospective targets and other compounds -- 3.2. Alkylating agents -- 3.3. Antitumor antibiotics -- 3.4. Antimetabolites cancer drugs -- 3.5. Epidermal growth factor receptor pathway inhibitors (EGFR inhibitors) -- 3.6. Vascular endothelial growth factor pathway inhibitors (VEGF inhibitors) -- 3.7. Immune checkpoint inhibitors -- 3.8. Proteasome inhibitors -- 3.9. mTOR protein kinase inhibitors -- 3.10. Biologic agents -- 3.11. BRAF inhibitors -- 3.12. Anaplastic lymphoma kinase inhibitor -- 4. Renoprotective effects of some novel anticancer therapeutics -- 4.1. The immune system -- 4.2. Sphingolipid signaling -- 4.3. DNA repair pathway -- 4.3.1. Poly(ADP-ribose) polymerase (PARP), PARP-1 -- 4.4. Histone modifications -- 4.4.1. Histone acetyltransferases (HATs) -- 4.4.2. Histone deacetylases (HDACs) -- 4.4.3. Sirtuins (SIRT) -- 4.5. Non-coding RNAs -- 5. Conclusions -- References -- Chapter Four: Chemotherapy induced gastrointestinal toxicities -- 1. Introduction -- 2. Chemotherapy-induced diarrhea -- 3. Chemotherapy-induced mucositis (CIM) -- 3.1. Intestinal epithelium -- 3.2. Pathobiological mechanisms of CIM -- 3.3. Chemotherapeutics implicated in CIM and CID -- 3.4. CIM and the microbiome.
|
| 505 |
8 |
|
|a 4. Emerging mechanisms underlying chemotherapy-induced gastrointestinal toxicity -- 5. Treatment of CID -- 5.1. Current and emerging pre-clinical strategies for treating CIM -- 6. The gut and chemotherapy-induced peripheral neuropathy -- 7. Conclusion -- References -- Chapter Five: Cardiac complications of cancer therapies -- 1. Introduction -- 2. Cancer therapeutic agents -- 2.1. Anthracyclines -- 2.1.1. Mechanisms of anthracycline cardiotoxicity -- 2.1.1.1. ROS and oxidative damage -- 2.1.1.2. Topoisomerase II -- 2.1.1.3. Apoptosis -- 2.1.1.4. Ferroptosis -- 2.1.1.5. Pyroptosis -- 2.2. Tyrosine kinase inhibitors -- 2.2.1. Mechanisms of tyrosine kinase inhibitor cardiotoxicity -- 2.2.1.1. QT prolongation -- 2.2.1.2. Left ventricular dysfunction -- 2.2.1.3. Hypertension -- 2.3. Fluorouracil and other anti-metabolites -- 2.3.1. Fluorouracil and anti-metabolites induced cardiac toxicity -- 2.4. Immune therapies -- 2.4.1. IC-associated cardiotoxicities -- 2.5. Radiation therapy -- 2.5.1. Cardiotoxicity due to radiation therapy -- 2.6. Alkylating agents -- 2.6.1. Cardiotoxicity of alkylating agents -- 2.7. Platinum-based agents -- 2.7.1. Cardiotoxicity of platinum-based agents -- 2.8. Proteasome inhibitors -- 2.8.1. Cardiotoxicity from proteasome inhibitors -- 3. Current and promising therapies to prevent chemotherapy-induced cardiotoxicity -- 3.1. Dexrazoxane -- 3.2. Neurohormonal blockade -- 3.3. Statins -- 3.4. Exercise therapy -- 3.5. Remote ischemic preconditioning intervention -- 4. Conclusions -- Acknowledgments -- References -- Chapter Six: Strategies to mitigate the toxicity of cancer therapeutics -- 1. Overview of organ specific toxicities -- 2. Cancer related cognitive impairment -- 3. Ocular toxicities -- 4. Ototoxicity -- 5. Oral mucosal toxicities -- 6. Gastrointestinal toxicities -- 7. Renal toxicity.
|
| 505 |
8 |
|
|a 8. Aromatase inhibitor-associated musculoskeletal syndrome -- 9. Chemotherapy induced peripheral neuropathy (CIPN) -- 10. Immunotherapy-induced autoimmunity -- 11. Putting it all together. What is the future of symptom science? -- References.
|
| 650 |
|
0 |
|a Cancer
|x Treatment
|x Complications.
|
| 650 |
|
0 |
|a Iatrogenic diseases
|x Prevention.
|
| 650 |
|
2 |
|a Drug-Related Side Effects and Adverse Reactions
|x therapy
|0 (DNLM)D064420Q000628
|
| 650 |
|
2 |
|a Antineoplastic Agents
|x adverse effects
|0 (DNLM)D000970Q000009
|
| 650 |
|
2 |
|a Radiotherapy
|x adverse effects
|0 (DNLM)D011878Q000009
|
| 650 |
|
2 |
|a Neoplasms
|x therapy
|0 (DNLM)D009369Q000628
|
| 650 |
|
6 |
|a Cancer
|x Traitement
|x Complications et s�equelles.
|0 (CaQQLa)201-0127518
|
| 650 |
|
6 |
|a Radioth�erapie
|x Complications et s�equelles.
|0 (CaQQLa)201-0200061
|
| 650 |
|
7 |
|a Cancer
|x Treatment
|x Complications
|2 fast
|0 (OCoLC)fst00845539
|
| 700 |
1 |
|
|a Gewirtz, David A.
|
| 700 |
1 |
|
|a Fisher, Paul B.
|
| 776 |
0 |
8 |
|i ebook version :
|z 9780323900881
|
| 776 |
0 |
8 |
|c Original
|z 0323900879
|z 9780323900874
|w (OCoLC)1288672440
|
| 830 |
|
0 |
|a Advances in cancer research ;
|v v. 155.
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/bookseries/0065230X/155
|z Texto completo
|
